Free Trial
LON:4BB

4basebio Final Earnings Results & Report

4basebio logo
GBX 517.50 -0.50 (-0.10%)
As of 11:41 AM Eastern

4basebio reported Final earnings on May 20, 2026. The company reported EPS of -GBX 1.09, while revenue was £1.69 million.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

4basebio EPS Results

Actual EPS
-GBX 1.09
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

4basebio Revenue Results

Actual Revenue
£1.69 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

4basebio Final Earnings FAQ

4basebio (LON:4BB) reported earnings of -GBX 1.09 per share for Final. The report was announced on Wednesday, May 20, 2026.

4basebio reported revenue of £1.69 million for Final.

4basebio Earnings Headlines

4basebio: Turning clinical credibility into commercial growth
This Could Be the Biggest Monetary Shift in 50 Years
The U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trades above $4,000 today. That gap means Washington's books show about $11 billion in gold that is actually worth more than $1 trillion. A bill in Congress would require repricing those reserves at market value. More than 60 million Americans qualify to move part of their savings into physical gold, tax-free and penalty-free, according to the 2026 Gold and Silver Guide.tc pixel
4basebio Plc - Result of General Meeting
4basebio Plc - Result of General Meeting
See More 4basebio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 4basebio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 4basebio and other key companies, straight to your email.

About 4basebio

4basebio (LON:4BB) is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.

View 4basebio Profile